Aspire Biopharma Holdings, Inc.
ASBP
Analytical Summary
On an absolute basis, Aspire Biopharma Holdings, Inc. shows mixed fundamentals. Return on Invested Capital remain bright spots. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.
6-Year Financial Trajectory
Annualinfo Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.
Bullish Indicators
- Return on Invested CapitalReturn on Invested Capital of 239.8% is excellent on an absolute basis (target > 10%)
Bearish Risks
- Interest CoverageInterest Coverage of -435.96x is weak on an absolute basis (target > 5x)
- FCF / Net IncomeFCF / Net Income of 0.20x is weak on an absolute basis (target > 1x)
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ | FY 2021 Dec 31, 2021 10-K ↗ | FY 2020 Feb 8, 2021 10-K ↗ |
|---|---|---|---|---|---|---|
| Net Income Growth YoY (%) |
-1768.9%
Weak
Weak
Year-over-year change in net income |
N/M |
33.6%
Excellent
Excellent
Year-over-year change in net income |
N/M | — | — |
| FCF Growth YoY (%) |
-756.8%
Weak
Weak
Year-over-year change in free cash flow |
— | — | — | — | — |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ | FY 2021 Dec 31, 2021 10-K ↗ | FY 2020 Feb 8, 2021 10-K ↗ |
|---|---|---|---|---|---|---|
| Effective Tax Rate (%) (%) | — |
-0.1%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
— | — | — | — |
| FCF / Net Income (x) |
0.20x
Weak
↑
Weak
Improving
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.20x
Weak
↓
Weak
Declining
Free cash flow relative to reported net income
Optimal:
> 1x
|
-0.15x
Weak
↓
Weak
Declining
Free cash flow relative to reported net income
Optimal:
> 1x
|
-0.42x
Weak
Weak
Free cash flow relative to reported net income
Optimal:
> 1x
|
9.37x
Excellent
Excellent
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ | FY 2021 Dec 31, 2021 10-K ↗ | FY 2020 Feb 8, 2021 10-K ↗ |
|---|---|---|---|---|---|---|
| Return on Invested Capital (%) |
239.8%
Excellent
Excellent
Return earned on debt + equity capital invested
Optimal:
> 10%
|
78.7%
Excellent
Excellent
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— | — | — | — |
| Return on Capital (%) (%) |
-1474.8%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
-818.2%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— | — | — | — |
| Return on Common Equity (%) (%) | — |
85.1%
Excellent
Excellent
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+467%)
|
— |
-33.6%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-324%)
|
— | — |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ | FY 2021 Dec 31, 2021 10-K ↗ | FY 2020 Feb 8, 2021 10-K ↗ |
|---|---|---|---|---|---|---|
| Working Capital (USD) | $-6.28M | $-1.54M | $-322.11K | $794.43K | $-475.00 | — |
| Total Equity (USD) | $-6.38M | $-1.54M | $-322.11K | $-9.94M | $-475.00 | $0.00 |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ | FY 2021 Dec 31, 2021 10-K ↗ | FY 2020 Feb 8, 2021 10-K ↗ |
|---|---|---|---|---|---|---|
| Sales/Revenue/Turnover (USD) | $6.20K | — | — | — | — | — |
| Net Income, GAAP (USD) | $-24.48M | $-1.31M | $4.46M | $3.34M | $-25.48K | — |
| Operating Cash Flow (USD) | $-4.92M | $-265.19K | $-653.11K | $-1.41M | $-238.60K | — |
Secondary lens
Benchmark Lens
Benchmarks are disabled until comparison data is defensible.
Unavailable
Benchmark Lens
Benchmarks are disabled until comparison data is defensible.
Benchmarks unavailable
Verdicts use absolute quality thresholds, not peer comparison — only 0 comparable companies are currently available for ranking.
Use Statement Evidence firstCompare ASBP with peers
Stack ASBP against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago 6 years · 22 quarters